This study is looking at a type of stem cell transplant called allogeneic stem cell transplantation (AlloSCT) for children, adolescents, and young adults with certain blood cancers (like leukemia and lymphoma) and blood disorders (like severe aplastic anemia). The study uses a special method called "alpha beta depletion" to prepare the donor stem cells. This process removes specific immune cells (alpha/beta T cells and CD19+ B cells) from the donor's cells before they are given to the patient. The main goal is to see how many side effects happen within one year after receiving these specially prepared stem cells. You may be able to join if you are between 1 day and 30 years old and have one of the listed conditions, such as high-risk acute leukemia in remission.

Study design

This is an interventional study with a planned enrollment of 20 participants. It is not specified if it is randomized or blinded.

What's involved

Participants will receive a stem cell transplant with specially prepared donor cells. All other treatment will follow standard care practices. You will be followed for engraftment (when new cells start growing), chimerism (presence of donor cells), immune recovery, graft-versus-host disease (GVHD), and quality of life.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint measures adverse events related to the stem cell administration at 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.